

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS : Buck, et al. Examiner: Hayes, Robert Clinton
U.S. PATENT NO.: 7,037,719 B1
SERIAL NUMBER : 09/890,469 Art Unit: 1649
FILING DATE : November 3, 2001
FOR : Enriched Central Nervous System Stem Cell and Progenitor Cell
Populations, and Methods for Identifying, Isolating and Enriching for
Such Populations

PTO-5
MAY 10 2006
PATENT & TRADEMARK OFFICE
Certificate of Correction Branch
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

*Certificate
MAY 17 2006
of Correction*

REQUEST FOR CERTIFICATE OF CORRECTION OF LETTERS PATENT

1. Attached, in duplicate, is Form PTO-1050, with at least one copy being suitable for printing.
2. The exact page and line number of the corrections are:

Claims:

In claim 6, column 27, line 38, "AC133 and monoclonal 5E12," should read --
AC133 and monoclonal antibody 5E12,--

In claim 7, column 27, line 50, "AC133 or monoclonal 5E12," should read --
AC133 or monoclonal antibody 5E12,--

In claim 8, column 28, line 2, "AC133⁺5E12⁺CD45^{-CD34}" should read --
AC133⁺5E12⁺CD45⁻CD34⁻.

In claim 20, column 29, line 5, "comprises a neural survival factor, NSF." should read -- comprises neural survival factor, NSF."

3. Please send the Certificate of Correction to:

Name: Ivor R. Elrifi, Esq.
Address: Mintz, Levin, Cohn, Ferris, Glovsky
and Popeo, P.C.
One Financial Center
Boston, MA 02111


REMARKS

Applicants enclose herewith Check No. 22469 in the amount of \$100.00 to cover the fee for the Certificate of Correction. Applicants request this Certificate of Correction to correct errors in this issued patent.

Should the Certificates Branch wish to discuss Applicant's request, the Certificates Branch is invited to telephone the undersigned attorney at 617/542-6000.

In connection with the foregoing matter, please charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account Number 50-0311, Reference No. 17810-510 NATL. A duplicate copy of this letter is provided for this purpose.

Respectfully submitted,


Ivor R. Elrifi, Reg. No. 39,529
Christina K. Stock, Reg. No. 45,899
Attorneys for Applicants
Telephone (617) 542-6000
Facsimile: (617) 542-2241
Customer No. 30623

Date: May 10, 2006

TRA 2150205v.1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS :	Buck, <i>et al.</i>	Examiner:	Hayes, Robert Clinton
U.S. PATENT NO.:	7,037,719 B1		
SERIAL NUMBER :	09/890,469	Art Unit:	1649
FILING DATE :	November 3, 2001		
FOR :	Enriched Central Nervous System Stem Cell and Progenitor Cell Populations, and Methods for Identifying, Isolating and Enriching for Such Populations		



Certificate of Correction Branch

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Enclosed herewith for filing in the above-identified application please find the following documents:

1. Request for Certificate of Correction of Letters Patent (2 pages);
2. Form PTO-1050 (1 page in duplicate);
3. Check No. 22469 in the amount of \$100.00;
4. Return Postcard

Although Applicants believe no additional fees are due with this submission, the Commissioner is hereby authorized to charge any fees that may be due, or credit any over payment of same, to Deposit Account Number 50-0311, Reference No. 17810-510 NATL. A duplicate copy of this Transmittal Letter is provided for this purpose.

Respectfully submitted,

Ivor R. Elrifi, Reg. No. 39,529
Christina K. Stock, Reg. No. 45,899

Attorneys for Applicants
Telephone (617) 542-6000
Facsimile: (617) 542-2241
Customer No. 30623

Date: May 10, 2006

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO.: 7,037,719 B1
DATED: May 2, 2006
INVENTORS: David W. Buck, Nobuko Uchida, Irving Weissman

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In claim 6, column 27, line 38, "AC133 and monoclonal 5E12," should read --AC133 and monoclonal antibody 5E12,--

In claim 7, column 27, line 50, "AC133 or monoclonal 5E12," should read -- AC133 or monoclonal antibody 5E12,--

In claim 8, column 28, line 2, "AC133⁺5E12⁺CD45⁻CD34⁻" should read -- AC133⁺5E12⁺CD45⁻CD34⁻--.

In claim 20, column 29, line 5, "comprises a neural survival factor, NSF." should read -- comprises neural survival factor, NSF."

MAILING ADDRESS OF SENDER:

Ivor R. Elrifi, Reg. No. 39,529
Christina K. Stock, Reg. No. 45,899
Attorneys for Applicants
c/o MINTZ LEVIN
Tel: (617) 542-6000
Fax: (617) 542-2241
Customer No.: 30623

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO.: 7,037,719 B1
DATED: May 2, 2006
INVENTORS: David W. Buck, Nobuko Uchida, Irving Weissman

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In claim 6, column 27, line 38, "AC133 and monoclonal 5E12," should read --AC133 and monoclonal antibody 5E12,--

In claim 7, column 27, line 50, "AC133 or monoclonal 5E12," should read -- AC133 or monoclonal antibody 5E12,--

In claim 8, column 28, line 2, "AC133⁺5E12⁺CD45⁻CD34⁻" should read -- AC133⁺5E12⁺CD45⁻CD34⁻--.

In claim 20, column 29, line 5, "comprises a neural survival factor, NSF." should read -- comprises neural survival factor, NSF."

MAILING ADDRESS OF SENDER:

Ivor R. Elrifi, Reg. No. 39,529
Christina K. Stock, Reg. No. 45,899
Attorneys for Applicants
c/o MINTZ LEVIN
Tel: (617) 542-6000
Fax: (617) 542-2241
Customer No.: 30623